Opthea (NASDAQ:OPT – Get Free Report) is projected to release its earnings data before the market opens on Wednesday, February 26th. Analysts expect Opthea to post earnings of ($0.43) per share for the quarter.
Opthea Stock Up 0.6 %
OPT opened at $5.02 on Monday. Opthea has a twelve month low of $1.79 and a twelve month high of $6.30. The business’s 50 day moving average is $4.37 and its 200-day moving average is $3.91.
Analysts Set New Price Targets
Several analysts recently commented on the stock. Canaccord Genuity Group raised shares of Opthea to a “strong-buy” rating in a research note on Tuesday, December 17th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Opthea in a research report on Wednesday, January 29th.
About Opthea
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Further Reading
- Five stocks we like better than Opthea
- Profitably Trade Stocks at 52-Week Highs
- Why Genuine Parts Company Is a Royally Good Buy Right Now
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Industrials Are Quietly Outpacing the Market: 3 Stocks to Watch
- Are Penny Stocks a Good Fit for Your Portfolio?
- These 5 Energy Stocks Hedge Inflation With Growth Potential
Receive News & Ratings for Opthea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opthea and related companies with MarketBeat.com's FREE daily email newsletter.
